Skip to main content
. 2021 Jan 21;24(2):102076. doi: 10.1016/j.isci.2021.102076

Figure 3.

Figure 3

Assessment of NfkB activity in genetically engineered CHO cells

(A) NfκB activity detected by a luciferase reporter assay in CHO-LOX-1-AT1, CHO-LOX-1-AT1mβ, and CHO-LOX-1-AT1mg treated with different concentration of oxLDL for 24 hr. The relative luminescence (NfkB-luciferase/control-renilla) in each cell type treated with 0μg/ml oxLDL in each cell type was normalized to 100% (n = 5). Data are represented as mean ± SEM. The differences were determined by one-way analysis of variance (ANOVA) with Bonferroni correction.

∗p < 0.05 vs. 0μg/ml oxLDL.

†p < 0.05 vs. concentration-matched oxLDL in CHO-LOX-1-AT1mβ.

(B) NfκB activity detected by a luciferase reporter assay in CHO-LOX-1-AT1 treated with vehicle, 2.5, 5μg/ml oxLDL, 10−8 M Ang II, or oxLDL in combination with Ang II for 24 hr. The relative luminescence (NfkB-luciferase/control-renilla) in each cell type treated with 0μg/ml oxLDL in each cell type was normalized to 100% (n = 5). Data are represented as mean ± SEM. The differences were determined by one-way ANOVA with Bonferroni correction. ∗p < 0.01 vs. vehicle treatment.